Day One Biopharmaceuticals Inc [DAWN] stock prices are down -5.02% to $14.96 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The DAWN shares have gain 8.64% over the last week, with a monthly amount glided 1.98%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Day One Biopharmaceuticals Inc [NASDAQ: DAWN] stock has seen the most recent analyst activity on April 25, 2023, when BofA Securities downgraded its rating to a Underperform and also revised its price target to $9 from $34. Previously, CapitalOne started tracking the stock with Overweight rating on February 08, 2023, and set its price target to $40. On February 03, 2023, Oppenheimer initiated with a Perform rating. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $35 on December 15, 2022. Needham initiated its recommendation with a Buy and recommended $40 as its price target on December 14, 2022. Goldman started tracking with a Buy rating for this stock on December 05, 2022, and assigned it a price target of $45. In a note dated December 01, 2022, BofA Securities initiated an Buy rating and provided a target price of $34 on this stock.
The stock price of Day One Biopharmaceuticals Inc [DAWN] has been fluctuating between $9.67 and $17.85 over the past year. Currently, Wall Street analysts expect the stock to reach $41.25 within the next 12 months. Day One Biopharmaceuticals Inc [NASDAQ: DAWN] shares were valued at $14.96 at the most recent close of the market. An investor can expect a potential return of 175.74% based on the average DAWN price forecast.
Analyzing the DAWN fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.48, Equity is -12.89 and Total Capital is -0.59. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.26 points at the first support level, and at 13.56 for the second support level. However, for the 1st resistance point, the stock is sitting at 15.84, and for the 2nd resistance point, it is at 16.72.
Ratios To Look Out For
It’s worth pointing out that Day One Biopharmaceuticals Inc [NASDAQ:DAWN]’s Current Ratio is 12.72. As well, the Quick Ratio is 12.72, while the Cash Ratio is 7.82.
Transactions by insiders
Recent insider trading involved Blackman Samuel C., HEAD OF R&D, that happened on Mar 25 ’24 when 10000.0 shares were sold. HEAD OF R&D, Blackman Samuel C. completed a deal on Mar 11 ’24 to sell 30000.0 shares. Meanwhile, HEAD OF R&D Blackman Samuel C. sold 20000.0 shares on Feb 27 ’24.
